As it is widely known that patients with MSI-H tumors can benefit from immunotherapy [69], routine clinical genetic testing for both POLD1/POLE and MSI-related mutations may help identify patients with endometrial and colorectal cancers who could respond well to immunotherapy [70]. This evidence concerns the gene POLD1 and colorectal cancer.